Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLK-6002
- Development stage
- Unknown
- Lead developer
- HLK Pharmacin
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HLK-6002 is a small molecule drug developed by Shenzhen Pharmacin Co., Ltd (also referred to as HLK Pharmacin) for the treatment of immune system diseases, with primary indications in anaphylaxis and plaque psoriasis. It is a repurposed or reformulated version of an undisclosed drug product. The mechanism of action has not been publicly disclosed. The drug has been investigated primarily as a topical ointment formulation, with Phase I clinical trials conducted to evaluate its safety, efficacy, and pharmacokinetics in both healthy volunteers and patients with plaque psoriasis[1][2][4]. As of the latest updates, it remains in early-stage clinical development.
Beyond the preview
Go deeper on HLK-6002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLK-6002.